Elevation of troponin T and N-terminal pro-B-type natriuretic peptide (nt- pro BNP) in heart failure patients with CKD

Shaik Mahmood

Assistant Professor, Dept. of Physiology, Deccan College of Medical Sciences, Hyderabad Telangana, India

Corresponding Author: Shaik Mohammad
Email: mahmood_shaikh2001@yahoo.co.in

Abstract
Elevation of Troponin T and N-Terminal pro-B-type natriuretic peptide (NT-proBNP) are commonly and strongly predictable biomarkers of Heart Failure (HF) patients with CKD. The present study included 150 people with CKD. We examined the association of baseline levels of elevation of TnT and NT-pro BNP with Heart Failure (HF) and CKD patients, after the adjustment for demographic factors, traditional cardiovascular risk factors and biomarkers of Chronic Kidney Disease. Constant medication application and mineral metabolism biomarkers cause Heart Failure and CKD. At base line, elevation of TnT levels ranged from < 5.0 to 1000 pg/ml and NT-proBNP levels ranged from < 5.0 to 35000 pg/ml. Compared to normal controls for TnT < 5.8 – 25.8 pg/ml and NT_proBNP 54 – 340 pg/ml. With this conclusion the elevation of TnT and NT-proBNP were strongly associated with incident of Heart Failure (HF) among with severe CKD. Elevations in these biomarkers may indicate subclinical changes in volume and myocardial stress that subsequently contribute to clinical Heart Failure (HF) with CKD.

Keywords: Cardiovascular disease, Heart failure, Kidney disease, Troponin T and N-Terminal pro-B-type natriuretic peptide (NT-proBNP).

Introduction
Raised Troponin T and N-Terminal Pro-B-type Natriuretic Peptide (NT-pro BNP) are more significant in cardiac problems and in chronic renal failure. However in heart attack, they rise and fall but in renal failure the rise is constant. Troponin regulates heart muscles and tissue contraction. NT-pro BNP is vasopeptide hormones that have major role in regulating blood pressure (BP) and volume through direct effects on the kidney and systemic vasculature and represent a favorable aspects of neurohumoral activation. Troponin is a group of three proteins Troponin C, T, and I Troponin I T are the cardiac markers, they regulate heart muscle and tissue contraction. These proteins are released after the damage of heart muscles. The greater the damage to the heart, the higher the Troponin levels in the blood. Troponin levels may be rise approximately 4 to 6 hours after heart damage. Troponin in blood remain raised up to two weeks. Three different natriuretic peptides have been characterized namely A type (atrial) natriuretic peptide, B type (brain) natriuretic peptide (BN) and C type natriuretic peptide. BNP is synthesized as amino acid precursor protein and undergoes intracellular modification to a pro hormone (ProBNP) which comprises 108 amino acids and is secreted from left ventricle (LV) in response to increased myocardial wall stress. It is also found in the kidney glomerular filtration. It has major role in the elimination of BNP. In contrast NT – pro - BNP is thought to be principally cleared by renal excretion.

Heart Failure (HF) is the most common cardiovascular complication among patients with Chronic Kidney Disease (CKD) and it imposes significant morbidity and mortality. Among people with CKD subclinical cardiac dysfunction (e.g. early changes in left ventricular structure and function) The cardiac biomarkers high sensitivity Troponin T (hs TnT) and N - terminal pro – B - type natriuretic peptide (NT – pro BNP) have been shown to predict heart failure in the general population. The use of hs TnT and NT – pro BNP to aid in the diagnosis of heart failure among patients with CKD. It has been limited because of concerns that elevated levels may be caused by reduced renal excretion. The elevation in TnT and NT – pro BNP would be independently associated with incident Heart Failure (HF) among patients with mild to severe Chronic Kidney Disease (CKD).

Material and Methods
The present study included 150 patients with end-stage renal failure undergoing chronic hemodialysis, all patients were examined by electrocardiography and two – dimensional echocardiography, at the Departments of Cardiology, Nephrology, Biochemistry and Physiology, Shadan Institute of Medical Sciences, Teaching Hospital & Research Centre, R.R District, Telangana State, India. Based on the examination results patients were found for concentric left ventricular hypertrophy, Acute Myocardial Infarction (AMI) and signs of Coronary Artery Disease (CAD) Heart Failure (HF). Blood was collected from patients before dialysis. Renal Function Test (RFT) was measured in Cobas clinical Analyser and serum electrolytes were measured in ST – 200 PLUS Electrolytes Analyzer Sensa Core. The serum TnT was measured on an ES 700 analyser (Roche Diagnostics) and NT – ProBNP was measured on Mini Vidas (Roche Diagnostics) We have examined the association of baseline levels of elevation of TnT and NT – pro BNP with Heart Failure (HF) and Chronic Kidney Disease (CKD) patients, after adjustment for their demographic facroes, traditional cardiovascular risk factors clinical and biomarkers of Heart Failure (HF) and Chronic Kidney Disease (CKD). The patients for constant medication application and mineral
metabolism biomarkers cause Heart Failure (HF) and Chronic Kidney Disease (CKD). At the base line elevation of TnT levels ranged from \(<_5.0\) to 1000 pg/ml and NT – pro BNP levels ranged from \(<_5.0\) to 35000 pg/ml. This is compared to normal controls for TnT \(<_5.0\) to 25.8 pg/ml and NT – pro BNP 54.5 to 340 pg/ml. With this conclusion elevation of TnT and NT- ProBNP were strongly associated with incident of Heart Failure (HF) among with the severe Chronic Kidney Disease (CKD). Elevation in these biomarkers may indicate subclinical changes in volume and myocardial stress that subsequent contributed to clinical Heart Failure (HF) and with Chronic Kidney Disease (CKD).

**Results**

Among participants in our study for Heart Failure (HF) with Chronic Kidney Disease (CKD) The elevated average mean SD + values were found as mean age was 58.5, for both male and female, body mass index mean 32.5 kg/m2, mean blood pressure systolic 150mm/Hg, diastolic 110 mm/Hg, renal function test mean blood urea 132.5 mg/dl, mean serum creatinine 8.50 mg/dl, mean serum uric acid 9.5 mg/dl. Mean serum potassium level was 6.5 mEq/L, Mean Glomerular Filtration Rate (GRF) was 225 Ru/ml and Mean 24 hours urinary protein was 1.75 g/day. Beside the above elevated values in Heart Failure (HF) and Chronic Kidney Disease (CKD) patients more significant for hTNT \(>10000\) pg/ml and NT- pro – BNP \(>35000\) pg/ml were found.

**Conclusion**

In conclusion among patients with Chronic Kidney Disease (CKD), elevated levels of hs TNT and NT- proBNP were strongly associated with incident with Heart Failure (HF), even after adjustment for a broad range of demographic, traditional, clinical and physiobiochemical may indicate early changes in volume and myocardial stress that subsequently contribute to clinical Heart Failure (HF).

**Conflict of Interest:** None.

**References**

8. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME et al, B-type natriuretic peptide (BNP) and

**Table 1: Demographic, Clinical and Physiobiochemical characteristics of Heart Failure (HF) and Chronic Kidney Disease (CKD) patients**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients</th>
<th>Controls</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>40 – 60</td>
<td>30 – 50</td>
<td>(&lt; 0.001)</td>
</tr>
<tr>
<td>Sex (Male%)</td>
<td>50 – 60</td>
<td>40 - 60</td>
<td></td>
</tr>
<tr>
<td>(Female%)</td>
<td>30 - 40</td>
<td>30 – 50</td>
<td></td>
</tr>
<tr>
<td>Body Mass Index kg/m2</td>
<td>35 – 40</td>
<td>30 – 35</td>
<td></td>
</tr>
<tr>
<td>Blood Pressure mm/Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>120 - 180</td>
<td>110 – 120</td>
<td></td>
</tr>
<tr>
<td>Diastolic</td>
<td>100 – 120</td>
<td>70 – 80</td>
<td></td>
</tr>
<tr>
<td>Renal Function Test (RFT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Urea (mg/dl)</td>
<td>80 – 185</td>
<td>15 – 40</td>
<td>(&lt; 0.001)</td>
</tr>
<tr>
<td>Serum Creatinine (mg/dl)</td>
<td>4.5 – 12.5</td>
<td>0.8 – 1.5</td>
<td></td>
</tr>
<tr>
<td>Serum Uric Acid (mg/dl)</td>
<td>8.5 – 10.5</td>
<td>3.5 – 7.0</td>
<td></td>
</tr>
<tr>
<td>Serum Potassium (mEq/L)</td>
<td>5.0 – 8.0</td>
<td>3.5 – 5.0</td>
<td></td>
</tr>
<tr>
<td>GRF (Ru/ml)</td>
<td>150 – 300</td>
<td>110 – 200</td>
<td></td>
</tr>
<tr>
<td>24 Hours Urinary Proteins (g/day)</td>
<td>1.0 – 2.5</td>
<td>0.08 – 0.9</td>
<td></td>
</tr>
<tr>
<td>hs TnT pg/ml</td>
<td>(&gt;10000)</td>
<td>5 – 25</td>
<td></td>
</tr>
<tr>
<td>NT – pro BNP pg/ml</td>
<td>(&gt;35000)</td>
<td>55 – 340</td>
<td>(&lt; 0.001)</td>
</tr>
</tbody>
</table>

P values \(<0.001\) are subject to all the parameters


48. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al, Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standards Committee. European Association of Echocardiography: Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–63.

How to cite this article: Mahmood S. Elevation of troponin T and N-terminal pro-B-type natriuretic peptide (nt-pro BNP) in heart failure patients with CKD. Int J Aesthet Health Rejuvenation 2019;2(2):26–9.